Porównaj metody

	Formulacja stałej dyspersji	Współczynnik podobieństwa rozpadu f1/f2	Dostarczanie leków za pomocą liposomów
Dziedzina	Farmakologia	Farmakologia	Farmakologia
Rodzina	Process / pipeline	Process / pipeline	Process / pipeline
Rok powstania	1971	1996	1965
Twórca	William Chiou and Solomon Riegelman	James Moore and Hector Flanner	Alec Bangham
Typ	solubility enhancement	similarity testing	formulation technology
Źródło pierwotne	Chiou, W. L., Riegelman, S. (1971). Pharmaceutical applications of solid dispersions. Journal of Pharmaceutical Sciences, 60(9), 1281-1302.	Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74.	Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipid films and the determination of membrane potential. Journal of Molecular Biology, 13(1), 238-252.
Inne nazwy	solid solution, amorphous dispersion, polymer-based formulation	f1, f2, similarity factor	liposomal formulation, vesicular delivery, lipid nanoparticles
Pokrewne	3	3	3
Podsumowanie	Solid dispersion is a formulation technique where a poorly soluble drug is molecularly dispersed in a hydrophilic polymer matrix, improving aqueous solubility and bioavailability. Introduced by Chiou and Riegelman in 1971, solid dispersions remain a key strategy for overcoming solubility-limited absorption.	The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release.	Liposomal encapsulation is a formulation technique using lipid bilayer vesicles (liposomes) to enclose drugs, improving bioavailability, reducing toxicity, and enabling targeted delivery. Developed by Alec Bangham in 1965, liposomes are now standard in pharmaceutical development, with several FDA-approved liposomal drugs on the market.